US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Acurx Pharmaceuticals, Inc. - Common Stock
(NQ:
ACXP
)
1.135
-0.005 (-0.44%)
Delayed Quote
Updated: 3:59 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acurx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
October 20, 2021
Via
AB Newswire
VIDEO Report: Acurx Pharmaceuticals’ Ibezapolstat In Focus As A Best-In-Class Treatment For Gram Positive Infections (NASDAQ: ACXP)
September 21, 2021
Via
AB Newswire
CEO In Focus: Acurx Pharma CEO Confident His Company’s Phase 2b Ibezapolstat Trial Can Lead To A Front-Line Treatment For C. difficile (NASDAQ: ACXP)
September 15, 2021
Via
AB Newswire
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
September 13, 2021
New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing...
Via
Newsfile
Topics
Death
Derivatives
Initial Public Offering
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
↗
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
↗
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
↗
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Acurx Pharmaceutical’s Reaches Another Milestone With Russell Microcap Inclusion; Shares Extend August Gains (NASDAQ: ACXP)
September 03, 2021
Via
AB Newswire
Acurx Pharmaceutical’s Is Disruptive To The Antibiotics Landscape- That’s Great News For Patients With Gram-Positive Infections (NASDAQ: ACXP)
September 01, 2021
Via
AB Newswire
Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better Drugs That Target Gram-Positive Infections
August 25, 2021
Via
AB Newswire
Acurx Pharmaceutical’s On Pace To Change The Antibiotics Landscape; Trial Data Shows 100% Sustained Clinical Cure In Treating Gram-Positive Infection CDI
August 17, 2021
Via
AB Newswire
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
August 12, 2021
Via
AB Newswire
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
↗
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Gram Positive Bacterial Infections Can Be Fatal; Acurx Pharmaceuticals Is One Of The Few Working To Change The Treatment Landscape (NASDAQ: ACXP)
August 09, 2021
Via
AB Newswire
Acurx Pharmaceuticals Leverages IPO Capital To Develop Most Significant Advance To Antibiotics In More Than 40 Years (NASDAQ: ACXP)
July 28, 2021
Via
AB Newswire
Topics
Initial Public Offering
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
↗
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
↗
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
↗
July 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...
Via
Benzinga
Acurx Pharmaceuticals On Pace To Deliver The Most Important Upgrade To Antibiotics Since The 1980s (NASDAQ: ACXP)
July 15, 2021
Via
AB Newswire
Topics
Initial Public Offering
Post-IPO Acurx Pharmaceuticals Expects To Deliver The First Meaningful Change To Antibiotics Market Since 1980s (NASDAQ: ACXP)
July 08, 2021
Via
AB Newswire
Topics
Initial Public Offering
Stocks That Hit 52-Week Lows On Friday
↗
July 02, 2021
Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) was the largest firm by market cap to set a new 52-week low...
Via
Benzinga
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
↗
July 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Acurx Pharmaceuticals Shares 15% Higher Post-IPO; On Track To Bring A New Class Of Effective Antibiotics To Market (NASDAQ: ACXP)
June 30, 2021
Via
AB Newswire
Topics
Initial Public Offering
60 Biggest Movers From Yesterday
↗
June 29, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
↗
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook
↗
June 28, 2021
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S....
Via
Benzinga
Topics
Stocks
Acurx Pharmaceuticals Shares Surge 31% Following Its Debut Public Offering; Low Share Count And $15 Million Presents A Compelling Investment Opportunity
June 28, 2021
Via
AB Newswire
Topics
Initial Public Offering
24 Stocks Moving in Monday's Pre-Market Session
↗
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...
Via
Benzinga
55 Biggest Movers From Friday
↗
June 28, 2021
Gainers IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger deal with TeraWulf. Alpha Teknova, Inc. (NASDAQ:...
Via
Benzinga
Software Startup Sprinklr Falls In Market Debut, More IPO News
↗
June 27, 2021
Shares of Sprinklr fell almost 9% in their market debut on Wednesday, valuing the startup at $3.7B. The software company counts Microsoft and Verizon as customers. Didi and Krispy Kreme are among...
Via
Talk Markets
Topics
Initial Public Offering
< Previous
1
2
3
4
5
6
7
8
Next >
